AGM/EGMApr 26, 2026, 05:30 AM
SVRA 2026 Annual Meeting Set; Proposes Share Increase, Plan Amendment
AI Summary
Savara Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 4, 2026. Key proposals include the election of six directors, increasing authorized common stock from 300 million to 600 million shares, and amending the 2024 Omnibus Incentive Plan to add 18.9 million shares. The company also provided an update on its investigational therapy, MOLBREEVI, with a US FDA Action Date of November 22, 2026, and expected decisions in the EU and UK in Q1 2027 and Q4 2026, respectively. Savara has strengthened its financial position with a $149.5 million equity financing, a $75 million royalty funding agreement, and an amended debt facility for up to $75 million upon FDA approval.
Key Highlights
- 2026 Annual Meeting of Stockholders to be held virtually on June 4, 2026.
- Proposal to elect six directors to the Board.
- Proposal to increase authorized common stock from 300,000,000 to 600,000,000 shares.
- Proposal to increase shares for 2024 Omnibus Incentive Plan by 18,900,000.
- MOLBREEVI BLA under US FDA Priority Review with November 22, 2026 Action Date.
- MOLBREEVI MAA decision expected Q1 2027 (EU) and Q4 2026 (UK).
- Completed $149.5 million equity financing.
- Secured $75 million royalty funding and up to $75 million additional debt funding.